339537-87-0

Basic information

• Product Name: [R]-7-{[2-(4-trifluoromethyl-phenyl)-pyridine-3-carbonyl]-amino}-quinoline-3-carboxylic acid (1-pyridin-2-yl-ethyl)-amide
• CAS NO: 339537-87-0
• Molecular Weight: 541.532
• Mol File: 339537-87-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: [R]-7-{[2-(4-trifluoromethyl-phenyl)-pyridine-3-carbonyl]-amino}-quinoline-3-carboxylic acid (1-pyridin-2-yl-ethyl)-amide(CAS DataBase Reference)
• NIST Chemistry Reference: [R]-7-{[2-(4-trifluoromethyl-phenyl)-pyridine-3-carbonyl]-amino}-quinoline-3-carboxylic acid (1-pyridin-2-yl-ethyl)-amide(339537-87-0)
• EPA Substance Registry System: [R]-7-{[2-(4-trifluoromethyl-phenyl)-pyridine-3-carbonyl]-amino}-quinoline-3-carboxylic acid (1-pyridin-2-yl-ethyl)-amide(339537-87-0)

Safety Data

• Hazardous Substances Data: 339537-87-0(Hazardous Substances Data)

Upstream product

• 339538-67-9 7-{[2-(4-trifluoromethyl-phenyl)-pyridine-3-carbonyl]-amino}-quinoline-3-carboxylic acid 
• 27854-90-6 (R)-1-(pyridin-2-yl)ethanamine 

Relevant articles and documents

7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B

This invention relates to compounds of Formula I that inhibit the secretion of apolipoprotein B, to pharmaceutical compositions comprising the compounds, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperliproproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or Syndrome X. This invention also relates to methods of reducing the secretion of apolipoprotein B and/or inhibiting microsomal triglyceride transfer protein.